SC
TRML

Stempoint Capital’s Tourmaline Bio TRML Stock Holding History

Stempoint Capital’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-126,400
Closed -$2.56M – 82
2024
Q4 		$2.56M Buy
126,400
+70,877
+128% +$1.78M 0.64% 39
2024
Q3 		$1.43M Buy
+55,523
New +$927K 0.43% 42
2024
Q2 		– Sell
-274,219
Closed -$6.28M – 72
2024
Q1 		$6.28M Buy
+274,219
New +$9.67M 1.66% 18

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Stempoint Capital's TRML Position: Q1 2025 in Review

Stempoint Capital sold out of Tourmaline Bio (TRML) in Q1 2025, closing a stake of 126,400 shares — an estimated $2.56M sold.

Stempoint Capital first reported a position in TRML in Q1 2024 and held it in 3 quarters. The position peaked at $6.28M in Q1 2024. 107 funds tracked by Wall St. Rank hold TRML as of Q1 2025.

  • Stempoint Capital reported no remaining Tourmaline Bio position as of Q1 2025 after selling out during the quarter.
  • Stempoint Capital sold 126,400 Tourmaline Bio shares in Q1 2025, an estimated $2.56M.
  • Stempoint Capital first reported a position in Tourmaline Bio in Q1 2024 and held it in 3 quarters.
  • Stempoint Capital's Tourmaline Bio position peaked at $6.28M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2025.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.